Details

Autor(en) / Beteiligte

• Matsusaka, Satoshi
• Mishima, Yuji
• Suenaga, Mitsukuni
• Terui, Yasuhito
• Kuniyoshi, Ryoko
• Mizunuma, Nobuyuki
• Hatake, Kiyohiko

Titel

Circulating endothelial progenitors and CXCR4‐positive circulating endothelial cells are predictive markers for bevacizumab

Ist Teil von

• Cancer, 2011-09, Vol.117 (17), p.4026-4032

Ort / Verlag

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Erscheinungsjahr

2011

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• BACKGROUND: Bevacizumab plus chemotherapy is a standard option in the treatment of metastatic colorectal cancer (mCRC). The aim of this study was to investigate the potential of circulating endothelial cell progenitors (CEPs) and phenotypical circulating endothelial cells (CECs) as surrogate markers of clinical outcome in mCRC patients to identify responders to bevacizumab in combination with chemotherapy. METHODS: A total of 69 patients with measurable mCRC were enrolled in this prospective study. Whole blood samples were analyzed before initiation of treatment and on days 4 and 14. Phenotypical CECs and CEPs were then isolated and enumerated by using flow cytometry. RESULTS: CEP levels of less than 0.04% on day 4 were significantly associated with longer progression‐free survival (PFS) and overall survival (OS) (P < .001, P = .002, respectively) as compared with levels of 0.04% or more. In addition, CXCR4‐positive CEC levels of less than 20% at baseline were significantly associated with longer PFS and OS as compared other indicators investigated (P < .001, P = .002, respectively). CONCLUSIONS: Levels of CEPs on day 4 and proportion of CXCR4‐positive CECs at baseline were correlated with the prognosis of bevacizumab combination chemotherapy, suggesting that these surrogate markers may play a core role in the selection of candidates for bevacizumab treatment. Cancer 2011;. © 2011 American Cancer Society. Levels of circulating endothelial progenitors on day 4 and the proportion of CXCR4‐positive circulating endothelial cells at baseline were correlated with the prognosis of bevacizumab combination chemotherapy, suggesting that these surrogate markers may play a core role in the selection of candidates for bevacizumab treatment.